The global high potency API market is characterized by the presence of many global, regional, and local vendors catering to the demand created by major pharmaceutical companies. The market is highly competitive, with players competing and collaborating to gain a substantial market share. Geographically fragmented market, novel product launches, rising collaborative partnerships, and decisions undertaken to achieve operational efficiency are key factors that aid market growth. The manufacturers compete based on cost, quality, and reliability. It is decisive for the manufacturers to provide cost-efficient and innovative products to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, manufacturers should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional, and foreign players with small market shares also have a considerable presence. The international players may strengthen their presence worldwide through acquisitions and mergers during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new players with innovative products to enter into the market and increase the global market share.
The global high potency API market consists of a large number of global and local players operating in the respective regions. There are few prominent players that have captured significant market share in the global high potency API market.
With respect to the current scope of the report, Piramal Pharma Solutions holds a significant market share in the global high potency API market. The company offers USFDA, UK-MHRA, PMDA Japan, and Health Canada accredited services to pharmaceutical companies. Piramal is a prominent player in contract development and the manufacturing organizations (CDMO) industry.
Additionally, CordenPharma International is observed to be one of the top players in the global high potency API market owing to its strong product portfolio and wide geographic presence. CordenPharma International operates in all the major markets including the Americas and Europe. AbbVie Inc. is a research-driven biopharmaceutical company focused on the manufacturing of target-specific products. It offers high potency manufacturing/analytical services to the customers across the globe.
Other prominent players operating in the global high potency API market are Lonza AG, Evonik Industries AG, Merck KGaA, and Teva Pharmaceutical Industries Ltd.
Threat of New Entrants
The threat of new entrants is medium in the global high potency API market. Any contract development and manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. However, the budget required for research and development of a product is low as compared to other industries. High potency APIs are specialized and manufactured for use in various pharmaceutical products. Moreover, the majority of the customers are using products of trusted sellers. The customers are likely to prefer established brands over new market players due to quality concerns and to maintain the quality of the final product, which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
The suppliers in the global high potency API market are raw material manufacturers. There are very few suppliers present in the global high potency API market. The switching cost of these suppliers is moderate due to the competition, and also the raw materials required for the manufacturing of high potency API is not easily available. The suppliers are likely to enter into long term partnerships with high potency API manufacturers. Due to the increasing research and development activities related to the high potency API and entry of major pharmaceutical companies in the market, a large number of customers are available.
Moreover, few suppliers are present to cater to the needs of the customers which leads to the competition between the existing suppliers. However, low-quality products are likely to damage the quality of the final product, and it can cause adverse effects. Hence, customers are selective about suppliers. Due to this, the overall bargaining power of suppliers in the global high potency API market is low to medium.
Threat of Substitutes
The threat of substitutes in the global high potency API market is low to medium. High potency API is used in the development and manufacturing of pharmaceutical products which are used for the treatment of various medical complications. There are limited options available in the market to serve the need of the customers and which eliminates the threat of substitutes. However, the increasing research and development activities and demand for efficient APIs are likely to provide new substitutes to the high potency API. Also, the high degree of switching cost decreases the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global high potency API market. The number of buyers is more as compared to the number of high potency API manufacturing companies. However, the high potency APIs are specialized and play an important role in pharmaceutical product manufacturing, and the buyers of the high potency API are moderately inclined towards quality products manufactured by trusted companies. As the products are manufactured for the treatment of medical complications such as cancer, there are limited substitutes available in the market in front of buyers. Also, most of the buyers are pharmaceutical companies and research organizations; they are likely to enter into the long-term agreements with the high potency API manufacturers for uninterrupted supply. Moreover, they can exert pressure on the manufacturers due to the low switching cost and intense rivalry in the market, which is responsible for the increased bargaining power of buyers.
Intensity of Rivalry
The rivalry in the global high potency API market is moderate to high. The low degree of product differentiation and a limited number of customers increases the intensity of rivalry in the market. The market is growing with a prominent growth rate and likely to provide opportunities for major players to expand their geographical boundaries which will initiate tough competition between major players to capture maximum market share in the emerging markets. Major players are trying to develop products under their own as a part of vertical integration. Players are engaged in developing a process to lower their manufacturing and logistics costs to increase profitability and to overcome the competition. Moreover, they are also developing advanced products for differentiating their brand from their competitors.
